KRAS and neoplasm: In a carcinogenesis-induced Kras-driven lung cancer, the novel RXR agonist MSU-42011 decreased tumor burden by reducing tumor-promoting CD206+ macrophages, immunosuppressive CD4-FOXP3 (Tregs), which led to increasing activated cytotoxic T cells [29].